WallStreetZenWallStreetZen

NASDAQ: SRPT
Sarepta Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for SRPT

Based on 13 analysts offering 12 month price targets for Sarepta Therapeutics Inc

Min Forecast
$75.00+20.19%
Avg Forecast
$129.39+107.35%
Max Forecast
$193.00+209.29%

Should I buy or sell SRPT stock?

Based on 13 analysts offering ratings for Sarepta Therapeutics Inc.

Buy
Strong Buy
5 analysts 38.46%
Buy
3 analysts 23.08%
Hold
4 analysts 30.77%
Sell
1 analysts 7.69%
Strong Sell
0 analysts 0%
Although SRPT's forecast from analysts indicates a "Buy", our proven Zen Rating quant model rates SRPT as a "Hold". Stocks with a Zen Rating of Hold have had an average return of +7.53% per year. Learn More

Be the first to know when Wall Street analysts revise their SRPT stock forecasts and price targets.

SRPT stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-04-21
lockedlocked$00.00+00.00%2025-04-16
lockedlocked$00.00+00.00%2025-04-11
lockedlocked$00.00+00.00%2025-04-11
lockedlocked$00.00+00.00%2025-04-03
RBC Capital
Bottom 3%
3
HoldDowngrades$87.00+39.42%2025-03-31
ScotiaBank
Bottom 7%
7
HoldMaintains$80.00+28.21%2025-03-20
Cantor Fitzgerald
Top 2%
99
Strong BuyReiterates$163.00+161.22%2025-03-19
Deutsche Bank
Top 24%
77
HoldMaintains$99.00+58.65%2025-03-19
HC Wainwright & Co.
Top 11%
90
SellReiterates$75.00+20.19%2025-01-30

1 of 2

Forecast return on equity

Is SRPT forecast to generate an efficient return?

Company
87.92%
Industry
142.9%
Market
80.27%
SRPT's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is SRPT forecast to generate an efficient return on assets?

Company
33.89%
Industry
35.65%
SRPT is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

SRPT earnings per share forecast

What is SRPT's earnings per share in the next 3 years based on estimates from 8 analysts?

Avg 1 year Forecast
$5.64+128.24%
Avg 2 year Forecast
$12.00+385.73%
Avg 3 year Forecast
$13.96+465.08%
SRPT's earnings are forecast to... subscribe to Premium to read more.
Forecast High Earnings Growth Forecast

SRPT revenue forecast

What is SRPT's revenue in the next 3 years based on estimates from 10 analysts?

Avg 1 year Forecast
$3.0B+58.99%
Avg 2 year Forecast
$3.8B+99.46%
Avg 3 year Forecast
$4.2B+120.39%
SRPT's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

SRPT earnings growth forecast

How is SRPT forecast to perform vs Biotechnology companies and vs the US market?

Company
83.31%
Industry
12.96%
Market
17.59%
SRPT's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Industry Forecast
SRPT's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Market Forecast
SRPT's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Savings Rate Forecast

SRPT revenue growth forecast

How is SRPT forecast to perform vs Biotechnology companies and vs the US market?

Company
30.93%
Industry
64.17%
Market
10.07%
SRPT's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
SRPT's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

SRPT vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
SRPT$62.40$129.39+107.35%Buy
VRNA$72.07$77.80+7.95%Strong Buy
TLX$17.40$22.00+26.44%Strong Buy
BPMC$89.50$129.10+44.25%Buy
LEGN$34.95$81.00+131.76%Strong Buy
View Top Biotech Stocks

Sarepta Therapeutics Stock Forecast FAQ

Is Sarepta Therapeutics Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 13 Wall Street analysts covering (NASDAQ: SRPT) stock is to Buy SRPT stock.

Out of 13 analysts, 5 (38.46%) are recommending SRPT as a Strong Buy, 3 (23.08%) are recommending SRPT as a Buy, 4 (30.77%) are recommending SRPT as a Hold, 1 (7.69%) are recommending SRPT as a Sell, and 0 (0%) are recommending SRPT as a Strong Sell.

If you're new to stock investing, here's how to buy Sarepta Therapeutics stock.

What is SRPT's earnings growth forecast for 2025-2027?

(NASDAQ: SRPT) Sarepta Therapeutics's forecast annual earnings growth rate of 83.31% is forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 12.96%, and it is also forecast to beat the US market's average forecast earnings growth rate of 17.59%.

Sarepta Therapeutics's earnings in 2025 is $235,239,000.On average, 8 Wall Street analysts forecast SRPT's earnings for 2025 to be $547,018,312, with the lowest SRPT earnings forecast at $126,141,695, and the highest SRPT earnings forecast at $757,820,490. On average, 8 Wall Street analysts forecast SRPT's earnings for 2026 to be $1,164,142,296, with the lowest SRPT earnings forecast at $810,217,810, and the highest SRPT earnings forecast at $1,530,195,791.

In 2027, SRPT is forecast to generate $1,354,325,159 in earnings, with the lowest earnings forecast at $1,188,642,894 and the highest earnings forecast at $1,617,524,657.

What is SRPT's revenue growth forecast for 2025-2027?

(NASDAQ: SRPT) Sarepta Therapeutics's forecast annual revenue growth rate of 30.93% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 64.17%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.07%.

Sarepta Therapeutics's revenue in 2025 is $1,901,979,000.On average, 10 Wall Street analysts forecast SRPT's revenue for 2025 to be $293,425,376,880, with the lowest SRPT revenue forecast at $280,878,741,713, and the highest SRPT revenue forecast at $322,049,450,287. On average, 9 Wall Street analysts forecast SRPT's revenue for 2026 to be $368,112,418,949, with the lowest SRPT revenue forecast at $319,672,164,499, and the highest SRPT revenue forecast at $413,094,644,383.

In 2027, SRPT is forecast to generate $406,745,253,654 in revenue, with the lowest revenue forecast at $386,341,931,536 and the highest revenue forecast at $433,704,256,688.

What is SRPT's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: SRPT) forecast ROA is 33.89%, which is lower than the forecast US Biotechnology industry average of 35.65%.

What is SRPT's Price Target?

According to 13 Wall Street analysts that have issued a 1 year SRPT price target, the average SRPT price target is $129.39, with the highest SRPT stock price forecast at $193.00 and the lowest SRPT stock price forecast at $75.00.

On average, Wall Street analysts predict that Sarepta Therapeutics's share price could reach $129.39 by Apr 21, 2026. The average Sarepta Therapeutics stock price prediction forecasts a potential upside of 107.35% from the current SRPT share price of $62.40.

What is SRPT's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: SRPT) Sarepta Therapeutics's current Earnings Per Share (EPS) is $2.47. On average, analysts forecast that SRPT's EPS will be $5.64 for 2025, with the lowest EPS forecast at $1.30, and the highest EPS forecast at $7.81. On average, analysts forecast that SRPT's EPS will be $12.00 for 2026, with the lowest EPS forecast at $8.35, and the highest EPS forecast at $15.77. In 2027, SRPT's EPS is forecast to hit $13.96 (min: $12.25, max: $16.67).

What is SRPT's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: SRPT) forecast ROE is 87.92%, which is considered strong.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.